Sino Biopharmaceutical Limited (HKEX:1177) Annual Report 2021



The latest annual report of Sino Biopharmaceutical Limited (1177) was published on 31 Dec 2021. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - 1177 Annual Results

Amounts in CNY

Total Revenue
26.86B
Gross Profit
21.53B
EBIT
4.23B
Net Tangible Assets
29.35B
Net Income
14.61B
Capital Expenditures
-1.71B

1177 Income Statement 2021 Annual Report

As per the latest Income Statement of 1177, the Net revenue increased by ¥3.214132B (14%) compared to the previous period. The operating income in 2021 increased by ¥130.40M (3%). The net income as per the annual report was 14.61B which increased by ¥11.837326B (427%) compared to previous year.

Income Statement Report (2021/2020)

20212020
Total Revenue26.86B23.65B
Gross Profit21.53B18.46B
Operating Income4.23B4.1B
Income Before Tax18.57B5.01B
Net Income14.61B2.77B

Balance Sheet - 1177 2021 Annual Report

Read further: 1177 Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Sino Biopharmaceutical Limited showed the company reduced the cash on balance sheet by ¥-690.27M (-6%). The Net tangible assets of 1177 on the balance sheet were at 29.35B which is ¥12.918742B (79%) more than previous annual report. The total stockholder equity also increased by ¥13.543956B (81%) compared to previous reporting period.

Balance Sheet Statement Report (2021/2020)

20212020
Cash10.57B11.26B
Total Assets60.54B 47.21B
Long Term Debt5.21B12.36B
Total Liabilities22.81B 24.79B
Total Shareholder Equity30.29B16.75B
Net Tangible Assets29.35B16.43B

Cash Flow Statement - 1177 2021 Annual Report

The 2021 annual cash flow statement of Sino Biopharmaceutical Limited showed that the net income increased by ¥11.837326B (427%) compared to previous reporting period. Also the capital expenditure of 1177 decreased by ¥-289.84M (-20%).

As of 2021, the total cash from investing activities was -2.52B and total cash from financing activities was -3.23B.

Cash Flow Statement Report (2021/2020)

20212020
Net Income14.61B2.77B
Capital Expenditures-1.71B-1.42B
Dividends Paid-938.49M-1.19B
Total Cash From From Investing Activities-2.52B-7.85B
Total Cash From From Financing Activities-3.23B2.23B

Sino Biopharmaceutical Limited Annual Report History

Income Statement

Income Statement history of Sino Biopharmaceutical Limited (HKEX:1177)

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Total Revenue26.86B23.65B24.23B20.89B
Cost Of Revenue5.33B5.18B4.93B4.2B
Gross Profit21.53B18.46B19.31B16.69B
Research Development----
Selling General Administrative12.7B11.63B11.8B10.27B
Non Recurring----
Other Operating Expenses4.6B2.74B2.56B2.3B
Total Operating Expenses22.63B19.55B19.28B16.77B
Operating Income4.23B4.1B4.95B4.12B
Total Other Income Expense Net14.34B914.62M737.54M7.31B
Ebit4.23B4.1B4.95B4.12B
Interest Expense-308.62M-323.37M-229.95M-153.26M
Income Before Tax18.57B5.01B5.69B11.43B
Income Tax Expense1.96B672.38M902.75M696.24M
Minority Interest7.44B5.67B5.61B8.34B
Net Income From Continuing Ops16.61B4.34B4.79B10.73B
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Charges----
Other Items----
Net Income14.61B2.77B2.76B9.05B
Net Income Applicable To Common Shares14.61B2.77B2.76B9.05B

Balance Sheet Statement

Balance Sheet Statement history of Sino Biopharmaceutical Limited (HKEX:1177)

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Cash10.57B11.26B11.91B6.68B
Short Term Investments569.5M956.01M5.62B4.35B
Net Receivables5.54B4.08B3.34B3.87B
Inventory1.94B1.88B1.66B1.21B
Total Current Assets23.5B22.79B24.91B18.54B
Long Term Investments25.17B13.86B2.02B1.07B
Property Plant Equipment8.52B8.39B7.63B5.8B
Good Will647.93M88.93M88.93M13.9B
Intangible Assets291.56M225.35M821.06M7.84B
Other Assets2.42B1.85B2.04B2.63B
Deferred Long Term Asset Charges334.87M463.37M557.35M470.56M
Total Assets60.54B47.21B37.51B49.78B
Accounts Payable1.69B1.95B1.81B1.83B
Short Long Term Debt6.52B1.55B22.13M48.11M
Other Current Liab1.92B3.22B2.06B1.68B
Long Term Debt5.21B12.36B7.88B507.07M
Other Liab1.94B1.22B903.91M2.05B
Deferred Long Term Liab772.46M699.36M503.15M504.98M
Minority Interest7.44B5.67B5.61B8.34B
Total Current Liabilities15.35B10.94B8.12B9.67B
Total Liab22.81B24.79B16.95B12.23B
Common Stock415.44M415.89M278.45M278.85M
Retained Earnings27.21B13.6B11.95B16.81B
Treasury Stock-9.92B-9.96B-10.25B-920.14M
Capital Surplus12.58B12.69B12.97B13.04B
Other Stockholder Equity-9.23B-9.49B-9.83B-462.85M
Total Stockholder Equity30.29B16.75B14.95B29.21B
Net Tangible Assets29.35B16.43B14.04B7.47B

Cash Flow Statement

Cash Flow Statement history of Sino Biopharmaceutical Limited (HKEX:1177)

31 Dec 202131 Dec 202031 Dec 201931 Dec 2018
Net Income14.61B2.77B2.76B9.05B
Depreciation922.74M1.64B1.4B1.16B
Change To Netincome-9.96B568.8M1.36B-5.42B
Change To Account Receivables-1.31B-198.79M196.31M-436.21M
Change To Liabilities-191.59M334.05M-143.2M870.48M
Change To Inventory-57.48M-221.45M-449.44M-102.16M
Change To Operating Activities1.22B347.52M113.52M-88.81M
Total Cash From Operating Activities5.37B5.33B5.32B5.09B
Capital Expenditures-1.71B-1.42B-1.45B-1.55B
Investments-4.39B-6.54B-2.45B-668.25M
Other Cashflows From Investing Activities4.41B383.13M343.89M510.46M
Total Cashflows From Investing Activities-2.52B-7.85B-3.82B-616.1M
Dividends Paid-938.49M-1.19B-819.69M-710.33M
Net Borrowings-1.5B5.34B5.17B304.67M
Other Cashflows From Financing Activities-452.37M-1.72B-1.51B-1.17B
Total Cash From Financing Activities-3.23B2.23B2.8B-2.18B
Effect Of Exchange Rate-649.71M280.01M95.05M242.47M
Change In Cash-1.02B-7.02M4.4B2.54B
Repurchase Of Stock-332.93M-195.37M-32.05M-604.42M